ReviewCurrent HIV/AIDS reports2023
Mpox and HIV: a Narrative Review.
Review in Current HIV/AIDS reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 64 citations in OpenAlex.
- CD4 Count and Clinical Outcomes of Mpox in People Living With HIV: A Systematic Review and Meta-Analysis.Health science reports · 2026Review
- Severe Clade I (subclade Ib) mpox in advanced HIV complicated by multidrug-resistant bacterial superinfection and ocular involvement: a case report from Uganda.Tropical medicine and health · 2026Article
- Automated Monkeypox Identification from Electronic Medical Records Using Large Language Models - Shenzhen City, Guangdong Province, China, 2023-2025.China CDC weekly · 2026Article
- Article
- Mpox in people living with and without HIV, including people on PrEP, during a multistate outbreak in Spain in 2022.Scientific reports · 2026Article
- Mpox Vaccination and Willingness to Participate in Mpox Vaccine Research Among Sexual and Gender Minority Adults with and Without HIV in the United States.Prevention science : the official journal of the Society for Prevention Research · 2026Article
- Syndemic convergence of mpox and HIV crisis in the Philippines: implications for integrated and responsive public health action.International journal for equity in health · 2026Article
- Acute Human Immunodeficiency Virus Infection Concurrent With Mpox Presenting With Proctitis and Disseminated Skin Lesions: A Case Report.Case reports in infectious diseases · 2026Article
- Mpox in People Living with HIV: Clinical Challenges, Preventive Strategies and Public Health Implications.Viruses · 2025Review
- Article
- Monkeypox Virus Transcriptional Profiles and Host Responses in Skin Lesion Swabs Among Individuals With Human Immunodeficiency Virus.The Journal of infectious diseases · 2025Article
- Article
- Genomic epidemiology of mpox virus during the 2022 outbreak in New York City.Nature communications · 2025Article
- Health insurance status and severe mpox disease outcomes among sexual minority men in NYC: a retrospective cohort study.BMC medicine · 2025Article
- Increased testing is needed for Mpox in DR Congo to urgently curb disease spread.Communications medicine · 2025Article
- Mpox: Characterization and clinical outcomes of patients in Colombian healthcare institutions.Global epidemiology · 2025Article
- Psychosocial and Behavioral Impacts of the Mpox Outbreak among People with and without HIV in the United States.AIDS and behavior · 2025Article
- Early Diagnosis and Monitoring of Adaptive Immune Response in a Cohort of Mild Mpox Patients During the 2022 Wave.Microorganisms · 2025Article
- Mpox and oral health among children in Africa.Frontiers in oral health · 2025Article
- Evaluating the advancements and efficacies in pharmacological Mpox treatments: a comprehensive review.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWe reviewed the available literature on mpox in People with HIV (PWH). We highlight special considerations of mpox infection related to epidemiology, clinical presentation, diagnostic and treatment considerations, prevention, and public health messaging in PWH. RECENT
findingsDuring the 2022 mpox outbreak, PWH were disproportionally impacted worldwide. Recent reports suggest that the disease presentation, management, and prognosis of these patients, especially those with advanced HIV disease, can widely differ from those without HIV-associated immunodeficiency. Mpox can often be mild and resolve on its own in PWH with controlled viremia and higher CD4 counts. However, it can be severe, with necrotic skin lesions and protracted healing; anogenital, rectal, and other mucosal lesions; and disseminated organ systems involvement. Higher rates of healthcare utilization are seen in PWH. Supportive, symptomatic care and single or combination mpox-directed antiviral drugs are commonly used in PWH with severe mpox disease. Data from randomized clinical control trials on the efficacy of therapeutic and preventive tools against mpox among PWH are needed to better guide clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.